Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran)

Ann Thorac Surg. 1999 Sep;68(3):1076-8. doi: 10.1016/s0003-4975(99)00876-0.


Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy. There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children. We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran). Emergent conduit revision with cardiopulmonary bypass was required for a thrombosed systemic-venous to pulmonary-arterial connection (completion modified Fontan procedure). Required doses of Danaparoid were consistently twofold that previously reported for adults.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use
  • Cardiopulmonary Bypass
  • Child, Preschool
  • Chondroitin Sulfates / therapeutic use*
  • Dermatan Sulfate / therapeutic use*
  • Drug Combinations
  • Female
  • Heart Defects, Congenital / surgery
  • Hemorrhage / drug therapy
  • Heparin / adverse effects*
  • Heparitin Sulfate / therapeutic use*
  • Humans
  • Thrombocytopenia / diagnosis*
  • Thrombocytopenia / drug therapy*
  • Thrombosis / drug therapy
  • Thrombosis / etiology


  • Anticoagulants
  • Drug Combinations
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid